Systemic Rosai-Dorfman-Destombes disease associated with a myelodysplastic syndrome. Efficacy of hematologic treatment

被引:0
|
作者
Deshayes, R. [1 ]
Eustache, M. [1 ]
Moreau, A. [2 ]
Peterlin, P. [3 ]
Neel, A. [1 ]
Masseau, A. [1 ]
Bodet-Milin, C. [4 ]
Hamidou, M. [1 ]
机构
[1] Hop Hotel Dieu, Serv Med Interne, F-44000 Nantes, France
[2] Hop Hotel Dieu, Lab Anatomopathol, F-44000 Nantes, France
[3] Hop Hotel Dieu, Serv Hematol, F-44000 Nantes, France
[4] Univ Nantes, Serv Med Nucl, CHU Hotel Dieu Nantes, CRCINA,Inserm,CNRS,Univ dAngers, F-44000 Nantes, France
来源
REVUE DE MEDECINE INTERNE | 2021年 / 42卷 / 04期
关键词
Destombes-Rosai-Dorfman; histiocytosis; myelodysplastic syndrome; azacytidine; LANGERHANS CELL HISTIOCYTOSIS; ERDHEIM-CHESTER DISEASE; SINUS HISTIOCYTOSIS; AUTOIMMUNE; NEOPLASMS;
D O I
10.1016/j.revmed.2021.01.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction. - We report an original observation of multifocal refractory Destombes-Rosai-Dorfman disease associated with a myelodysplastic syndrome. The treatment of myelodysplasia allowed a good and prolonged response of both pathologies. Case report. - A 35-year-old patient was investigated for bilateral exophthalmia, histologically related to Destombes-Rosai-Dorfman disease. The extension workup showed sinus, kidney and lymph node involvement. It was treated unsuccessfully with corticosteroids, colchicine, methotrexate, infliximab, cladribine and tociluzimab. The secondary appearance of myelodysplasia (AREB IPSS score intermediate 2) led to induction treatment with aracytin and idarubicin, and maintenance with azacytidine for 2 years. With 5 years of follow-up, the patient is in remission both of the myelodysplastic syndrome and Destombes-Rosai-Dorfman disease. Conclusion. - Our observation discusses the interest of the treatment of myelodysplastic syndrome for the management of associated extra-hematological manifestations. (C) 2021 Societe Nationale Francaise de Medecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:281 / 284
页数:4
相关论文
共 31 条
  • [21] MEK Inhibition With Trametinib for the treatment of MAP2K1-Mutated Rosai-Dorfman-Destombes Disease Arising from the Nasopharynx in a Paediatric Patient
    Cuerden, Claire
    Alsalem, Mohammad
    Sproson, Eleanor
    Burgess, Andrea
    Jogai, Sanjay
    Portess, Howard
    Deem, Karen
    Ismail-Koch, Hasnaa
    Abla, Oussama
    Bate, Jessica
    PEDIATRIC BLOOD & CANCER, 2025,
  • [22] Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders
    Papo, Matthias
    Cohen-Aubart, Fleur
    Trefond, Ludovic
    Bauvois, Adeline
    Amoura, Zahir
    Emile, Jean-Francois
    Haroche, Julien
    CURRENT ONCOLOGY REPORTS, 2019, 21 (07)
  • [23] Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim–Chester Disease, Destombes–Rosai–Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders
    Matthias Papo
    Fleur Cohen-Aubart
    Ludovic Trefond
    Adeline Bauvois
    Zahir Amoura
    Jean-François Emile
    Julien Haroche
    Current Oncology Reports, 2019, 21
  • [24] Rituximab Treatment in a Child with Rosai-Dorfman Disease and Systemic Lupus Erythematosus
    Alqanatish, Jubran Theeb
    Houghton, Kristin
    Bond, Mason
    Senger, Christof
    Tucker, Lori B.
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (08) : 1783 - 1785
  • [25] MAP2K1-driven mixed Langerhans cell histiocytosis, Rosai-Dorfman-Destombes disease and Erdheim-Chester disease, clonally related to acute myeloid leukemia
    Bonometti, Arturo
    Ferrario, Giuseppina
    Parafioriti, Antonina
    Giardino, Demostene
    Simonetti, Federico
    Ginori, Alessandro
    Passoni, Emanuela
    Berti, Emilio
    JOURNAL OF CUTANEOUS PATHOLOGY, 2021, 48 (05) : 637 - 643
  • [26] Development of Disseminated Histiocytic Sarcoma in a Patient With Autoimmune Lymphoproliferative Syndrome and Associated Rosai-Dorfman Disease
    Venkataraman, Girish
    McClain, Kenneth L.
    Pittaluga, Stefania
    Rao, V. Koneti
    Jaffe, Elaine S.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2010, 34 (04) : 589 - 594
  • [27] KIT V560D-Mutated Systemic Mastocytosis Associated With High-Risk Myelodysplastic Syndrome: A Unique Case of Systemic Mastocytosis-Associated Hematologic Neoplasm
    Medawar, Georgio
    Sakalabaktula, Krishna
    Magri, Jenna
    Rinker, Elizabeth
    Baratam, Praneeth
    CASE REPORTS IN HEMATOLOGY, 2024, 2024
  • [28] Successful treatment by azacitidine therapy of intestinal Behcet's disease associated with myelodysplastic syndrome
    Tanaka, Hiroaki
    Shimizu, Naomi
    Tougasaki, Emi
    Kawajiri, Chika
    Hashimoto, Shinichiro
    Takeda, Yusuke
    Sakai, Shio
    Takeuchi, Masahiro
    Ohwada, Chikako
    Sakaida, Emiko
    Takagi, Toshiyuki
    Nakaseko, Chiaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (04) : 520 - 524
  • [29] Successful treatment by azacitidine therapy of intestinal Behçet’s disease associated with myelodysplastic syndrome
    Hiroaki Tanaka
    Naomi Shimizu
    Emi Tougasaki
    Chika Kawajiri
    Shinichiro Hashimoto
    Yusuke Takeda
    Shio Sakai
    Masahiro Takeuchi
    Chikako Ohwada
    Emiko Sakaida
    Toshiyuki Takagi
    Chiaki Nakaseko
    International Journal of Hematology, 2013, 97 : 520 - 524
  • [30] Phenotypic intrafamilial variability including H syndrome and Rosai–Dorfman disease associated with the same c.1088G > A mutation in the SLC29A3 gene
    Hamza Chouk
    Mohamed Ben Rejeb
    Lobna Boussofara
    Haїfa Elmabrouk
    Najet Ghariani
    Badreddine Sriha
    Ali Saad
    Dorra H’Mida
    Mohamed Denguezli
    Human Genomics, 15